Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Compugen Ltd (CGEN)
NASDAQ:CGEN
Holding CGEN?
Track your performance easily
CGEN Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$1.35 - $3.03
Previous Close$1.53
Volume323.07K
Average Volume (3M)319.05K
Market Cap
$136.10M
Enterprise Value$86.76M
Total Cash (Recent Filing)$50.69M
Total Debt (Recent Filing)$1.35M
Price to Earnings (P/E)79.7
Beta2.38
Next Earnings
Feb 20, 2025EPS Estimate
$0.07Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.02
Shares Outstanding86,620,000
10 Day Avg. Volume629,271
30 Day Avg. Volume319,052
Standard Deviation0.35
R-Squared0.15
Alpha-0.01
Financial Highlights & Ratios
Price to Book (P/B)1.70
Price to Sales (P/S)8.33
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit2.76
Enterprise Value/Ebitda-3.97
Forecast
1Y Price Target
$4.00Price Target Upside161.44% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
Compugen News
PremiumCompany Announcements
Compugen Bolsters Cancer Therapy Portfolio with New Patent
PremiumCompany Announcements
Compugen Reports Strong Q3 2024 Results and Progress
PremiumCompany Announcements
Compugen’s Financial Surge and Promising Drug Trials
PremiumPre-Earnings
Compugen (CGEN) Q3 Earnings Cheat Sheet
PremiumCompany Announcements
Compugen Showcases Promising Data on Ovarian Cancer Therapy
Ownership Overview
―
Insiders
1.57% Mutual Funds
7.83% Other Institutional Investors
89.62% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
CGEN FAQ
What was Compugen Ltd’s price range in the past 12 months?
Compugen Ltd lowest stock price was $1.35 and its highest was $3.03 in the past 12 months.
What is Compugen Ltd’s market cap?
Currently, no data Available
When is Compugen Ltd’s upcoming earnings report date?
Compugen Ltd’s upcoming earnings report date is Feb 20, 2025 which is in 60 days.
How were Compugen Ltd’s earnings last quarter?
Compugen Ltd released its earnings results on Nov 12, 2024. The company reported $0.01 earnings per share for the quarter, beating the consensus estimate of -$0.095 by $0.105.
Is Compugen Ltd overvalued?
According to Wall Street analysts Compugen Ltd’s price is currently Undervalued.
Does Compugen Ltd pay dividends?
Compugen Ltd does not currently pay dividends.
What is Compugen Ltd’s EPS estimate?
Compugen Ltd’s EPS estimate is $0.07.
How many shares outstanding does Compugen Ltd have?
Compugen Ltd has 89,536,430 shares outstanding.
What happened to Compugen Ltd’s price movement after its last earnings report?
Compugen Ltd reported an EPS of $0.01 in its last earnings report, beating expectations of -$0.095. Following the earnings report the stock price went down -8.046%.
Which hedge fund is a major shareholder of Compugen Ltd?
Among the largest hedge funds holding Compugen Ltd’s share is ARK Investment Management LLC. It holds Compugen Ltd’s shares valued at 2M.
---
Compugen Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$4.00 (161.44% Upside)
$4.00 (161.44% Upside)
Hedge Fund Trend
Increased
By 3.9K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Neutral
Last 7 Days ▲ 0.9%
Last 30 Days >0.1%
Last 30 Days >0.1%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-17.29%
12-Months-Change
Fundamentals
Return on Equity
2.81%
Trailing 12-Months
Asset Growth
82.69%
Trailing 12-Months
Company Description
Compugen Ltd
Compugen Ltd. engages in the research, development, and commercialization of therapeutic and diagnostic biomarker product candidates including proteins and monoclonal antibodies. It focuses its research and development on immuno-oncology and autoimmune diseases. The company was founded by Eli Mintz, Simchon Faigler, and Amir Natan on February 10, 1993 and is headquartered in Holon, Israel.
---
CGEN Earnings Call
Q3 2024
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted significant financial improvements and promising clinical data, particularly for COM701 and COM503. However, there remain challenges in treating platinum-resistant ovarian cancer and in refining biomarker strategies. The company's partnerships and development plans indicate a positive outlook.Read More>---
CGEN Stock 12 Month Forecast
Average Price Target
$4.00
▲(161.44% Upside)
Technical Analysis
Best Analysts Covering CGEN
1 Year
1 Year Success Rate
3/14 ratings generated profit
1 Year Average Return
-12.31%
reiterated a buy rating last month
Copying Asthika Goonewardene's trades and holding each position for 1 Year would result in 21.43% of your transactions generating a profit, with an average return of -12.31% per trade.
---